Limits...
IGFBP3 mRNA expression in benign and malignant breast tumors.

Ren Z, Shin A, Cai Q, Shu XO, Gao YT, Zheng W - Breast Cancer Res. (2007)

Bottom Line: Cancer tissues had significantly lower IGFBP3 expression than benign tumor tissues (p < 0.001).IGFBP3 expressions in both tumor and adjacent tissues were higher in patients who had proliferative benign tumors than in those who had non-proliferative benign tumors.Among patients with benign breast disease, IGFBP3 expression in the tumor was significantly higher than that in their adjacent normal tissue.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University, S-1121 MCN, 1161 21st Ave, S, Nashville, TN 37232-2587, USA.

ABSTRACT

Introduction: Most previous studies have focused on evaluating the association between circulating insulin-like growth factor binding protein 3 (IGFBP-3) levels and breast cancer risk. Emerging evidence over the past few years suggests that IGFBP-3 may act directly on mammary epithelial cells.

Methods: To understand the role of IGFBP-3 in breast tumorigenesis, we investigated IGFBP3 mRNA expression levels in benign and malignant breast tumors and their adjacent normal tissues using real-time quantitative PCR.

Results: Cancer tissues had significantly lower IGFBP3 expression than benign tumor tissues (p < 0.001). IGFBP3 expressions in both tumor and adjacent tissues were higher in patients who had proliferative benign tumors than in those who had non-proliferative benign tumors. Among patients with benign breast disease, IGFBP3 expression in the tumor was significantly higher than that in their adjacent normal tissue. There were no apparent associations of IGFBP3 expression in cancer tissues with either overall survival or disease-free survival in a cohort of 521 patients with breast cancer.

Conclusion: Our findings suggest that the expression level of IGFBP3 in breast tissues may be involved in breast tumorigenesis.

Show MeSH

Related in: MedlinePlus

IGFBP3 expression in tumor tissues. Results are shown for differences between benign breast disease (BBD) and cancer (a) and between grades for BBD and stages for cancer (b). Values of p were calculated with a linear regression model including adjustment for age and menopausal status. Ct, threshold cycle; IGFBP3, gene encoding insulin-like growth factor binding protein 3.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC1851392&req=5

Figure 1: IGFBP3 expression in tumor tissues. Results are shown for differences between benign breast disease (BBD) and cancer (a) and between grades for BBD and stages for cancer (b). Values of p were calculated with a linear regression model including adjustment for age and menopausal status. Ct, threshold cycle; IGFBP3, gene encoding insulin-like growth factor binding protein 3.

Mentions: Figure 1 shows the distribution of gene expression in tumor tissues by patient groups. Table 2 presents median and interquartile ranges for the expression levels of the IGFBP3 gene in the tumor tissue and adjacent normal tissue of patients with breast cancer or BBD. The expression levels of IGFBP3 mRNA were substantially lower in tumor tissues from patients with cancer than those from patients with BBD (p < 0.001). In the adjacent normal tissues, however, IGFBP3 expression levels were somewhat higher in patients with cancer than in patients with BBD, although the difference was not statistically significant. Among patients with BBD, IGFBP3 expression in both tumor and adjacent tissues was higher in patients who had proliferative tumors than those who had non-proliferative tumors. Among patients with cancer, the gene expression levels in both tumor and adjacent normal tissues were elevated in advanced stage cancer; however, the difference was not statistically significant. The expression levels in cancer tissues did not differ by estrogen receptor (ER) or progesterone receptor status. Table 3 presents the study result by menopausal status. No apparent modifying effect by menopausal status was found. The difference in IGFBP3 mRNA level by BBD histology groups was not statistically significant in postmenopausal women, perhaps as a result of a small sample size.


IGFBP3 mRNA expression in benign and malignant breast tumors.

Ren Z, Shin A, Cai Q, Shu XO, Gao YT, Zheng W - Breast Cancer Res. (2007)

IGFBP3 expression in tumor tissues. Results are shown for differences between benign breast disease (BBD) and cancer (a) and between grades for BBD and stages for cancer (b). Values of p were calculated with a linear regression model including adjustment for age and menopausal status. Ct, threshold cycle; IGFBP3, gene encoding insulin-like growth factor binding protein 3.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC1851392&req=5

Figure 1: IGFBP3 expression in tumor tissues. Results are shown for differences between benign breast disease (BBD) and cancer (a) and between grades for BBD and stages for cancer (b). Values of p were calculated with a linear regression model including adjustment for age and menopausal status. Ct, threshold cycle; IGFBP3, gene encoding insulin-like growth factor binding protein 3.
Mentions: Figure 1 shows the distribution of gene expression in tumor tissues by patient groups. Table 2 presents median and interquartile ranges for the expression levels of the IGFBP3 gene in the tumor tissue and adjacent normal tissue of patients with breast cancer or BBD. The expression levels of IGFBP3 mRNA were substantially lower in tumor tissues from patients with cancer than those from patients with BBD (p < 0.001). In the adjacent normal tissues, however, IGFBP3 expression levels were somewhat higher in patients with cancer than in patients with BBD, although the difference was not statistically significant. Among patients with BBD, IGFBP3 expression in both tumor and adjacent tissues was higher in patients who had proliferative tumors than those who had non-proliferative tumors. Among patients with cancer, the gene expression levels in both tumor and adjacent normal tissues were elevated in advanced stage cancer; however, the difference was not statistically significant. The expression levels in cancer tissues did not differ by estrogen receptor (ER) or progesterone receptor status. Table 3 presents the study result by menopausal status. No apparent modifying effect by menopausal status was found. The difference in IGFBP3 mRNA level by BBD histology groups was not statistically significant in postmenopausal women, perhaps as a result of a small sample size.

Bottom Line: Cancer tissues had significantly lower IGFBP3 expression than benign tumor tissues (p < 0.001).IGFBP3 expressions in both tumor and adjacent tissues were higher in patients who had proliferative benign tumors than in those who had non-proliferative benign tumors.Among patients with benign breast disease, IGFBP3 expression in the tumor was significantly higher than that in their adjacent normal tissue.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University, S-1121 MCN, 1161 21st Ave, S, Nashville, TN 37232-2587, USA.

ABSTRACT

Introduction: Most previous studies have focused on evaluating the association between circulating insulin-like growth factor binding protein 3 (IGFBP-3) levels and breast cancer risk. Emerging evidence over the past few years suggests that IGFBP-3 may act directly on mammary epithelial cells.

Methods: To understand the role of IGFBP-3 in breast tumorigenesis, we investigated IGFBP3 mRNA expression levels in benign and malignant breast tumors and their adjacent normal tissues using real-time quantitative PCR.

Results: Cancer tissues had significantly lower IGFBP3 expression than benign tumor tissues (p < 0.001). IGFBP3 expressions in both tumor and adjacent tissues were higher in patients who had proliferative benign tumors than in those who had non-proliferative benign tumors. Among patients with benign breast disease, IGFBP3 expression in the tumor was significantly higher than that in their adjacent normal tissue. There were no apparent associations of IGFBP3 expression in cancer tissues with either overall survival or disease-free survival in a cohort of 521 patients with breast cancer.

Conclusion: Our findings suggest that the expression level of IGFBP3 in breast tissues may be involved in breast tumorigenesis.

Show MeSH
Related in: MedlinePlus